Research areas
病毒性肝炎、肝癌
Work Experience
消化內科疾病、慢性肝病診治20餘年經驗
Award
臺中榮民總醫院部級/院級優良醫師、行政院退輔會優良醫師
Academic Works
學術著作:
A.期刊論文-
1.Lin MS, Liao SC, Peng YC, Yang SS, Yeh HZ, Chang CS. Application of endoscopic US-guided tissue adhesive injection as a rescue therapy for post-tissue adhesive variceal obturation-related gastric wall bleeding. Gastrointest Endosc. 2014 Mar;79(3):514-5. (IF: 6.501, Gastroenterology & Hepatology, 10/79 = 12.65%)
2. Chang SC, Yang SS*, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health Qual Life Outcomes. 2014 Jun 18;12:97. doi: 10.1186/1477-7525-12-97. (co-first author) (IF: 2.143, Health policy & services, 25/77 = 32.5%)
3. Lee SW, Lee TY, Lien HC, Yang SS, Yeh HZ, Chang CS. Characteristics of Symptom Presentation and Risk Factors in Patients with Erosive Esophagitis and Nonerosive Reflux Disease. Med Princ Pract. 2014;23(5):460-4. doi: 10.1159/000363661. Epub 2014 Jul 8. (IF: 1.469, Medicine, General & Internal, 72/155 = 46.45%)
4. Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol. 2014 Aug 28;20(32):11384-93. doi: 10.3748/wjg.v20.i32.11384. (IF: 3.365, Gastroenterology & Hepatology, 30/79 = 37.97%)
5. Lee SW, Lien HC, Lee TY, Yang SS, Yeh HZ, Chang CS. Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease. World J Gastroenterol. 2014 Sep 14;20(34):12277-82. (IF: 3.365, Gastroenterology & Hepatology, 30/79 = 37.97%)
6. Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut. 2015 Feb;64(2):303-11. doi: 10.1136/gutjnl-2014-307080. Epub 2014 Apr 19. (IF: 16.658, Gastroenterology & Hepatology, 2/79 = 2.5%)
7. Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep. 2015 Jul 1;5:11710. doi: 10.1038/srep11710. (IF: 4.259, Multidisciplinary, 10/64 = 15.6%)
8. Chang SC, Hung CT, Li SF, Lee HM, Chung YC, Pai LW, Yang SS*. Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study. J Formos Med Assoc. 2015 Sep; 114(9):829-834. (IF: 2.452, Medicine, General & Internal, 42/155 = 27.1%)
9. Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatol Int. 2015 Sep 23. [Epub ahead of print] (IF: 2.164, Gastroenterology & Hepatology, 57/79 = 72.2%)
10. Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Sci Rep. 2015 Oct 15;5:15255. doi: 10.1038/srep15255. (IF: 4.259, Multidisciplinary, 10/64 = 15.6%)
11. Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, Lee CM, Yang SS, Chu HC, Wang TE, Chen BW, Chuang WL, Soon MS, Lin CY, Chiou ST, Kuo HS, Chen DS. Taiwan Hepatoma Study Group. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 2016 Sep;151(3):472-80. (IF: 18.392, Gastroenterology & Hepatology, 1/79 = 1.3%)
12. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International 2016 Dec;36(12):1755-1764. (IF: 4.116, Gastroenterology & Hepatology, 18/79 = 22.8%)
13. Chen YT, Chang CH, Yeh HZ, Chang CS, Yang SS*. HBV reactivation in a non-Hodgkin lymphoma patient with resolved HBV receiving rituximab maintenance therapy. Annals of Clinical Case Reports 2016;1:Article 1130. (non-SCI)
14. Lee LH, Hwang JI, Cheng YC, Wu CY, Lee SW, Yang SS, Yeh HZ, Chang CS, Lee TY. Comparable outcomes of ultrasound versus computed tomography in the guidance of radiofrequency ablation for hepatocellular carcinoma. PLoS One 2017 Jan 9;12(1):e0169655. doi: 10.1371/journal.pone.0169655. eCollection 2017. (IF: 2.806, Multidisciplinary, 15/64 = 23.4%)
15. Chen MC, Hung HC, Chang HJ, Yang SS, Tsai WC, Chang SC. Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Patients. BMC Health Serv Res. 2017 Feb 17;17(1):148. (IF: 1.827, Health care sciences & services, 49/90 = 54.4%)
16. Huang YJ, Chang CS, Peng YC, Yeh HZ, Yang SS*. On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy. J Chin Med Assoc. 2017 Mar 14. pii: S1726-4901(17)30031-X. doi: 10.1016/j.jcma.2016.12.005. [Epub ahead of print] (IF: 1.252, Medicine, General & Internal, 82/155 = 52.9%)
17. Huang YJ, Chang CS, Peng YC, Yeh HZ, Yang SS. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One. 2017 Mar 28;12(3):e0174046. doi: 10.1371/journal.pone.0174046. eCollection 2017. (IF: 2.806, Multidisciplinary, 15/64 = 23.4%)
18.Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population. Hepatobiliary Pancreat Dis Int. 2017 Apr;16(2):176-180. (IF: 1.500, Gastroenterology & Hepatology, 72/80 = 90.0%)
19. Lee SW, Yang SS, Lee TY, Yeh HZ, Lu IT, Chang CS. Oral direct acting antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype. J Gastrointestin Liver Dis. 2017 Jun;26(2): 205-206. (IF: 1.964, Gastroenterology & Hepatology, 63/80 = 78.8%)
20. Liao YJ, Li YC, Lee SW, Wu CY, Yang SS, Yeh HZ, Chang CS, Lee TY. Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up. J Chin Med A ssoc. 2017 Dec;80(12):758-765. doi: 10.1016/j.jcma.2017.07.009. Epub 2017 Sep 30. (IF: 1.252, Medicine, General & Internal, 82/155 = 52.9%)
21. Yang SS, Hung CT, Li SF, Lee HM, Chung YC, Chen HH, Chang SC. Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study. J Formos Med Assoc. 2018 Jul;117(7):566-571. (IF: 2.452, Medicine, General & Internal, 42/155 = 27.1%)
22. Lee TY, Chen CY, Lia HC, Hsu YC, Yang SS*. The ultra-short virological dynamics in response to entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation. Antivir Ther. 2018;23(1):77-85. doi: 10.3851/IMP3183. (IF:2.594, Infectious diseases, 41/84 = 48.8%)
23. Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):45-48. doi: 10.1016/j.hbpd.2018.01.007. Epub 2018 Jan 31. (IF: 1.500, Gastroenterology & Hepatology, 72/80 = 90.0%)
24. Lin YC, Lee SW, Yeh HZ, Chang CS, Yang SS*. The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy. Int J Clin Pharm. 2018 Feb;40(1):169-174. doi: 10.1007/s11096-017-0584-6. Epub 2018 Jan 10. (IF: 1.555, Pharmacology & Pharmacy, 197/257=76.6%)
25. Lin WT, Chen YM, Chen DY, Lan JL, Chang CS, Yeh HZ, Yang SS*. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018 Jan;27(1):66-75. doi: 10.1177/0961203317711009. Epub 2017 May 23. (IF: 2.454, Rheumatology; 18/30=60%)
26. Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observation study. Sci Rep. 2018 Sep; 8(1):13699. doi: 10.1038/s41598-018-32060-7 (IF: 4.259, Multidisciplinary, 10/64 = 15.6%)
27. Lee TY, Yang SS*. The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world. J Formos Med Assoc. 2018 Nov;117(11):1036-1037. (Letter) (IF: 2.452, Medicine, General & Internal, 42/155 = 27.1%)
28. Chen YM, Huang WN, Liao TL, Chen JP, Yang SS, Chen HH, Hsieh TY, Hung WT, Chen YH, Chen DY. Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. Ann Rheum Dis. 2019 Jan 3. doi:10.1136/annrheumdis-2018-214400. [Epub ahead of print] (Letter) (IF: 12.350, Rheumatology; 2/30=6.7%)
B.研討會論文
1.Shih CC, Yang SS*, Lin YF, Yeh HZ, Chang CS. Peginterferon-α plus ribavirin for HIV-HCV co-infected patients: A single center case-series report. 2014-10 TDDW (Taiwan Digestive Disease Week).
2.Chang SC, Yang SS*. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. 2014-10 TDDW.
3.Yang SS, Chang SC, Hung CT, Pai SL, Lee HM. Hepatitis B Virus-Related Mortality in Rheumatoid Arthritis Patients Undergoing Long-Term Low-Dose Glucocorticoids Treatment: A Nationwide Population-Based Cohort Study. 2014-10 TDDW.
4.Huang YJ, Lee TY, Chang CH, Yeh HZ, Chang CS, Yang SS*. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-refractory renal transplant recipients with chronic hepatitis B. 2014-10 TDDW.
5.Lee SW, Lian HC, Yang SS, Ko CW, Yeh HZ, Chang CS. Concomitant overlapping functional gastrointestinal disorders on the quality of life and presentation of patients with gastroesophageal reflux disease. 2014-10 TDDW.
6.Wei HY, Lee TY, Lee SW, Yeh HZ, Chang CS, Yang SS*. Risk factors for hepatocellular carcinoma rupture and mortality- A single center experience. 2015-03 消化系聯合學術演講年會
7.Huang YJ, Pen YC, Tung CF, Yeh HZ, Yang SS*. Comparison between HBeAg seroconversion and HBeAgseroclearance in HBeAg-positive antiviral treatment naïve patients treated with entecavir.2015-03 消化系聯合學術演講年會
8.Yang SS, Huang CW, Lin WT, Shih KC, Yeh HZ, Chang CS. Association of Hepatitis B Virus Infection and Glomerulonephritis in Taiwan: A Population-based Case-Controlled Study 2015-03 APASL annual meeting, Istanbul, Turkey
9.Huang YK, Lee TY, Lee SW, Lu ID, Yang SS, Yeh HZ. Transarterial chemoembolization after withdrawal of sorafenib therapy in patients with advanced hepatocellular carcinoma. 2016-03 TDDW.
10.Lin YC, Lee SW, Yeh HZ, Chang CS, Yang SS*. Glucocorticoid pulse therapy and hepatitis B flares. 2016-03 TDDW.
11.Yang SS, Lin YC, Lee SW, Yeh HZ, Chang CS,.Glucocorticoid Pulse Therapy and Hepatitis B Flares: A Retrospective Cohort Study. 2016-11 AASLD (American Association for the Study of Liver Diseases).
12.Lee SW, Ko CW, Yang SS, Lee TY, Yeh HZ, Chang CS. Metabolic abnormality in non-alcoholic fatty liver disease patients within a lean Chinese population. 2017-03 消化醫學春季年會
13.Lee TY, Yang SS, Chen CY, Lai SC, Hsu YC. The virological responses of entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation. 2017-03 消化醫學春季年會
14.Yang SS, Chuang WL, Chen CY, Chang TC, Liu CJ, Kao JH. Taiwanese subgroup analysis of a phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Efficacy and safety results at week 48. 2017-09 TDDW.
15.Chuang WL, Chang TC, Chen CY, Yang SS, Liu CJ, Kao JH. A phase 3 study comparing TAF to TDF in patients with HBeAg-negative CHB: Efficacy and safety results at week 96. 2017-09 TDDW.
16.Lee SW, Lee TY, Yang SS, Yeh HZ, Chang CS. Analysis of clinical factors associated with time to progression in advanced HCC patients with sorafenib: A single center experience. 2017-09 TDDW
17.Lee TY, Chen CY, Lai SC, Hsu YC, Yang SS*. The ultrashort viral kinetics of entecavir or lamivudine during chronic hepatitis B with spontaneous severe acute exacerbation. 2017-10 AASLD.
18.Lin WT, Yang SS*, Lee TY, Yeh HZ, Ko CW, Tung CF. Association between suatained virologic response and liver-related events among chronic hepatitis C patients treated with pegylated interferon-based regimen. 2018-09 TDDW.
C.專書
1. Yang SS, Kao JH. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2015 Jan;9(1):9-20. (IF: 2.743, Gastroenterology & Hepatology, 42//79 = 53.1%)
2.Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int. 2016 Mar;10(2):258-66. (IF: 2.164, Gastroenterology & Hepatology, 57/79 = 72.2%)
3. Yang SS, JH Kao. Direct-Acting Antiviral Agents for Chronic Hepatitis C. Formosan J Med 2017 21(2): 125-134. (non-SCI)
4. Chen YM, Yang SS, DY Chen. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological targeted therapy: A narrative review. J Microbiol Immunol Infect 10 Oct 2017 [Epub ahead of print] (IF: 2.973, Microbiology, 50/124 = 40.3%)